Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06887673 · ClinicalTrials.gov registry record · Early Phase 1
Lipid Mediators & Cancer: Montelukast, SPM, and Almonds
A Early Phase 1 study, sponsored by University of South Florida.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 56
- Enrollment target
NCT06887673 is a Early Phase 1 study that has not yet begun recruiting, run by University of South Florida. The registered enrollment target is 56 participants.
The verdict
NCT06887673, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of South Florida.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to create a prospective investigation to examine the effects of montelukast, almonds/almond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in cancer patients (colorectal cancer, sarcoma, brain tumors, endometrial cancer, and ovarian cancer). The focus will be on assessing changes in lipid mediator concentrations, TAM reprogramming, and immune cell function in treated versus untreated patients. It is hypothesized that montelukast will reduce the pro-inflammatory effects of leukotriene B4 (LTB4), while SPMs and almonds/almond oil will shift the balance toward pro-resolving mediators, enhancing anti-inflammatory and immune-stimulatory responses and reprogramming TAMs.
Interventions
- OTHER No Interventions
- DRUG Montelukast 10 Mg Oral Tablet
- DIETARY_SUPPLEMENT Sports Pro Resolve 4 g
- DIETARY_SUPPLEMENT Double Wood SPM 4 g
- DIETARY_SUPPLEMENT 20 California Sweet Almonds
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-03 |
| Est. Completion | 2026-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06887673
The ClinicalTrials.gov registry entry for NCT06887673 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which No Interventions is the first listed.
NCT06887673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06887673 about?
NCT06887673 is a clinical study titled "Lipid Mediators & Cancer: Montelukast, SPM, and Almonds". The purpose of this study is to create a prospective investigation to examine the effects of montelukast, almonds/almond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in cancer patients (colorectal cancer, sarcoma, brain tumors, endomet...
What is the current status of trial NCT06887673?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 56 participants. The study started on 2025-03. Estimated completion is 2026-03.
What interventions are being tested in trial NCT06887673?
The interventions under investigation include: No Interventions (OTHER), Montelukast 10 Mg Oral Tablet (DRUG), Sports Pro Resolve 4 g (DIETARY_SUPPLEMENT), Double Wood SPM 4 g (DIETARY_SUPPLEMENT), 20 California Sweet Almonds (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06887673?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.